{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:36:00Z","timestamp":1789058160304,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fighting smart diseases requires smart vaccines. Novel ways to present protective immunogenic peptide epitopes to human immune systems are needed. Herein, we focus on Self Assembling Protein Nanoparticles (SAPNs) as scaffolds\/platforms for vaccine delivery that produce strong immune responses against<jats:italic>Toxoplasma gondii<\/jats:italic>in HLA supermotif, transgenic mice. Herein, we present a useful platform to present peptides that elicit CD4<jats:sup>+<\/jats:sup>, CD8<jats:sup>+<\/jats:sup>T and B cell immune responses in a core architecture, formed by flagellin, administered in combination with TLR4 ligand-emulsion (GLA-SE) adjuvant. We demonstrate protection of HLA-A*11:01, HLA-A*02:01, and HLA-B*07:02 mice against toxoplasmosis by (i) this novel chimeric polypeptide, containing epitopes that elicit CD8<jats:sup>+<\/jats:sup>T cells<jats:italic>,<\/jats:italic>CD4<jats:sup>+<\/jats:sup>T helper cells, and IgG2b antibodies, and (ii) adjuvant activation of innate immune TLR4 and TLR5 pathways. HLA-A*11:01, HLA-A*02:01, and HLA-B*07:02q11 transgenic mouse splenocytes with peptides demonstrated predicted genetic restrictions. This creates a new paradigm-shifting vaccine approach to prevent toxoplasmosis, extendable to other diseases.<\/jats:p>","DOI":"10.1038\/s41598-020-73210-0","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T10:02:42Z","timestamp":1602496962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Kamal","family":"El Bissati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Paulillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil K.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Karch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Estes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Estes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lykins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Burkhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1130-9631","authenticated-orcid":false,"given":"Rima","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"73210_CR1","unstructured":"McLeod R, V. T. C., Boyer K. in Nelson Textbook of Pediatrics, 20th Edition Ch. 290, 1723\u20131732 (Elsevier, New York, 2015)."},{"key":"73210_CR2","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/cid\/cis258","volume":"54","author":"R McLeod","year":"2012","unstructured":"McLeod, R. et al. Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981\u20132009). Clin. Infect Dis. 54, 1595\u20131605. https:\/\/doi.org\/10.1093\/cid\/cis258 (2012).","journal-title":"Clin. Infect Dis."},{"key":"73210_CR3","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1016\/j.vaccine.2010.03.028","volume":"28","author":"TG Tan","year":"2010","unstructured":"Tan, T. G. et al. Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine 28, 3977\u20133989. https:\/\/doi.org\/10.1016\/j.vaccine.2010.03.028 (2010).","journal-title":"Vaccine"},{"key":"73210_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1745-7580-6-12","volume":"6","author":"H Cong","year":"2010","unstructured":"Cong, H. et al. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 6, 12. https:\/\/doi.org\/10.1186\/1745-7580-6-12 (2010).","journal-title":"Immunome Res."},{"key":"73210_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.vaccine.2010.11.015","volume":"29","author":"H Cong","year":"2010","unstructured":"Cong, H. et al. Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine 29, 754\u2013762. https:\/\/doi.org\/10.1016\/j.vaccine.2010.11.015 (2010).","journal-title":"Vaccine"},{"key":"73210_CR6","doi-asserted-by":"publisher","first-page":"e85955","DOI":"10.1172\/jci.insight.85955","volume":"1","author":"K El Bissati","year":"2016","unstructured":"El Bissati, K. et al. Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii. JCI Insight 1, e85955. https:\/\/doi.org\/10.1172\/jci.insight.85955 (2016).","journal-title":"JCI Insight"},{"key":"73210_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.pt.2010.06.004","volume":"26","author":"FL Henriquez","year":"2010","unstructured":"Henriquez, F. L., Woods, S., Cong, H., McLeod, R. & Roberts, C. W. Immunogenetics of Toxoplasma gondii informs vaccine design. Trends Parasitol. 26, 550\u2013555. https:\/\/doi.org\/10.1016\/j.pt.2010.06.004 (2010).","journal-title":"Trends Parasitol."},{"key":"73210_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.colsurfb.2009.08.022","volume":"75","author":"RC Anderson","year":"2010","unstructured":"Anderson, R. C. et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf. B Biointerfaces 75, 123\u2013132. https:\/\/doi.org\/10.1016\/j.colsurfb.2009.08.022 (2010).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"73210_CR9","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1016\/j.vaccine.2009.07.081","volume":"27","author":"SL Baldwin","year":"2009","unstructured":"Baldwin, S. L. et al. Enhanced humoral and Type1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27, 5956\u20135963. https:\/\/doi.org\/10.1016\/j.vaccine.2009.07.081 (2009).","journal-title":"Vaccine"},{"key":"73210_CR10","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1128\/CVI.00235-12","volume":"19","author":"CB Fox","year":"2012","unstructured":"Fox, C. B., Baldwin, S. L., Vedvick, T. S., Angov, E. & Reed, S. G. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clin Vaccine Immunol 19, 1633\u20131640. https:\/\/doi.org\/10.1128\/CVI.00235-12 (2012).","journal-title":"Clin Vaccine Immunol"},{"key":"73210_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41541-017-0024-6","volume":"2","author":"K El Bissati","year":"2017","unstructured":"El Bissati, K. et al. Protein nanovaccine confers robust immunity against Toxoplasma. NPJ Vaccines 2, 24. https:\/\/doi.org\/10.1038\/s41541-017-0024-6 (2017).","journal-title":"NPJ Vaccines"},{"key":"73210_CR12","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.vaccine.2014.03.092","volume":"32","author":"K El Bissati","year":"2014","unstructured":"El Bissati, K. et al. Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. Vaccine 32, 3243\u20133248. https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.092 (2014).","journal-title":"Vaccine"},{"key":"73210_CR13","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.4049\/jimmunol.0901957","volume":"183","author":"SA Kaba","year":"2009","unstructured":"Kaba, S. A. et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J. Immunol. 183, 7268\u20137277. https:\/\/doi.org\/10.4049\/jimmunol.0901957 (2009).","journal-title":"J. Immunol."},{"key":"73210_CR14","unstructured":"Burkhard, P. Peptidic nanoparticles as drug delivery and antigen display systems. US8575110B2 (2004)."},{"key":"73210_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.nano.2006.04.007","volume":"2","author":"S Raman","year":"2006","unstructured":"Raman, S., Machaidze, G., Lustig, A., Aebi, U. & Burkhard, P. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomed. Nanotechnol. Biol. Med. 2, 95\u2013102. https:\/\/doi.org\/10.1016\/j.nano.2006.04.007 (2006).","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"73210_CR16","unstructured":"Burkhard, P. Self-assembling peptide nanoparticles useful as vaccines. US 8546337 (2008)."},{"key":"73210_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048304","author":"SA Kaba","year":"2012","unstructured":"Kaba, S. A. et al. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0048304 (2012).","journal-title":"PLoS ONE"},{"key":"73210_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2006.04.007","author":"SK Raman","year":"2014","unstructured":"Raman, S. K., Machaidze, G., Lustig, A., Aebi, U. & Burkhard, P. Flagellin-containing protein nanoparticles as a vaccine platform. J. Mol. Biol. https:\/\/doi.org\/10.1016\/j.nano.2006.04.007 (2014).","journal-title":"J. Mol. Biol."},{"key":"73210_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1084\/jem.20041672","volume":"201","author":"O Cerede","year":"2005","unstructured":"Cerede, O. et al. Synergistic role of micronemal proteins in Toxoplasma gondii virulence. J. Exp. Med. 201, 453\u2013463. https:\/\/doi.org\/10.1084\/jem.20041672 (2005).","journal-title":"J. Exp. Med."},{"key":"73210_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/glycob\/11.7.541","volume":"11","author":"EV Lourenco","year":"2001","unstructured":"Lourenco, E. V. et al. Toxoplasma gondii micronemal protein MIC1 is a lactose-binding lectin. Glycobiology 11, 541\u2013547. https:\/\/doi.org\/10.1093\/glycob\/11.7.541 (2001).","journal-title":"Glycobiology"},{"key":"73210_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/s0065-2776(08)60695-1","volume":"45","author":"V Nussenzweig","year":"1989","unstructured":"Nussenzweig, V. & Nussenzweig, R. S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 45, 283\u2013334. https:\/\/doi.org\/10.1016\/s0065-2776(08)60695-1 (1989).","journal-title":"Adv. Immunol."},{"issue":"41","key":"73210_CR22","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.1016\/j.vaccine.2017.02.040","volume":"35","author":"L Seth","year":"2012","unstructured":"Seth, L. et al. Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants. Vaccine 35(41), 5448\u20135454.","journal-title":"Vaccine"},{"key":"73210_CR23","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/pro.204","volume":"18","author":"JA Garnett","year":"2009","unstructured":"Garnett, J. A. et al. Detailed insights from microarray and crystallographic studies into carbohydrate recognition by microneme protein 1 (MIC1) of Toxoplasma gondii. Protein Sci. 18, 1935\u20131947. https:\/\/doi.org\/10.1002\/pro.204 (2009).","journal-title":"Protein Sci."},{"key":"73210_CR24","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1128\/EC.00081-14","volume":"13","author":"IJ Blader","year":"2014","unstructured":"Blader, I. J. & Koshy, A. A. Toxoplasma gondii development of its replicative niche: in its host cell and beyond. Eukaryot Cell 13, 965\u2013976. https:\/\/doi.org\/10.1128\/EC.00081-14 (2014).","journal-title":"Eukaryot Cell"},{"key":"73210_CR25","doi-asserted-by":"publisher","first-page":"e0143087","DOI":"10.1371\/journal.pone.0143087","volume":"10","author":"CF Pinzan","year":"2015","unstructured":"Pinzan, C. F. et al. Vaccination with recombinant microneme proteins confers protection against experimental toxoplasmosis in mice. PLoS ONE 10, e0143087. https:\/\/doi.org\/10.1371\/journal.pone.0143087 (2015).","journal-title":"PLoS ONE"},{"key":"73210_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1083\/jcb.152.3.563","volume":"152","author":"M Reiss","year":"2001","unstructured":"Reiss, M. et al. Identification and characterization of an escorter for two secretory adhesins in Toxoplasma gondii. J. Cell Biol. 152, 563\u2013578. https:\/\/doi.org\/10.1083\/jcb.152.3.563 (2001).","journal-title":"J. Cell Biol."},{"key":"73210_CR27","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.4049\/jimmunol.150.9.3951","volume":"150","author":"JR Mineo","year":"1993","unstructured":"Mineo, J. R. et al. Antibodies to Toxoplasma gondii major surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine intestine after peroral infection. J. Immunol. 150, 3951\u20133964 (1993).","journal-title":"J. Immunol."},{"key":"73210_CR28","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/ncomms5098","volume":"5","author":"MH Lamarque","year":"2014","unstructured":"Lamarque, M. H. et al. Plasticity and redundancy among AMA-RON pairs ensure host cell entry of Toxoplasma parasites. Nat. Commun. 5, 4098. https:\/\/doi.org\/10.1038\/ncomms5098 (2014).","journal-title":"Nat. Commun."},{"key":"73210_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1475-2875-12-136","volume":"12","author":"ME McCoy","year":"2013","unstructured":"McCoy, M. E. et al. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine. Malar J. 12, 136. https:\/\/doi.org\/10.1186\/1475-2875-12-136 (2013).","journal-title":"Malar J."},{"key":"73210_CR30","doi-asserted-by":"publisher","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","volume":"113","author":"JS Chahal","year":"2016","unstructured":"Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl. Acad. Sci. USA 113, E4133-4142. https:\/\/doi.org\/10.1073\/pnas.1600299113 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73210_CR31","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1128\/JVI.80.3.1414-1426.2006","volume":"80","author":"Y Li","year":"2006","unstructured":"Li, Y. et al. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J. Virol. 80, 1414\u20131426. https:\/\/doi.org\/10.1128\/JVI.80.3.1414-1426.2006 (2006).","journal-title":"J. Virol."},{"key":"73210_CR32","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/s0264-410x(99)00421-1","volume":"18","author":"S Nitayaphan","year":"2000","unstructured":"Nitayaphan, S. et al. A phase I\/II trial of HIV SF2 gp120\/MF59 vaccine in seronegative thais. AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine 18, 1448\u20131455. https:\/\/doi.org\/10.1016\/s0264-410x(99)00421-1 (2000).","journal-title":"Vaccine"},{"key":"73210_CR33","doi-asserted-by":"publisher","unstructured":"Reed, S. G., Fox, C. B. & Carter, D. Emulsion-based vaccine adjuvants. In Future Medicine. https:\/\/doi.org\/10.2217\/9781780840604 (2012).","DOI":"10.2217\/9781780840604"},{"key":"73210_CR34","doi-asserted-by":"publisher","first-page":"126794","DOI":"10.1155\/2011\/126794","volume":"2011","author":"S Babapoor","year":"2011","unstructured":"Babapoor, S. et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Res. Treat. 2011, 126794. https:\/\/doi.org\/10.1155\/2011\/126794 (2011).","journal-title":"Influenza Res. Treat."},{"key":"73210_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/1756-3305-5-273","volume":"5","author":"M Meng","year":"2012","unstructured":"Meng, M. et al. Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1 (SAG1) and 14-3-3 protein in BALB\/c mice. Parasite Vectors 5, 273. https:\/\/doi.org\/10.1186\/1756-3305-5-273 (2012).","journal-title":"Parasite Vectors"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73210-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T14:51:45Z","timestamp":1696863105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73210-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73210"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73210-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"13 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.B. has an interest in Alpha-O Peptides. This is a company with a focus on SAPNs. This company has patents or patents pending on relevant technology. Patent applications pertinent to this work have been filed. Otherwise, the authors have no competing interests. Funding sources did mot influence the decision to submit the paper, nor in the design, collection of data, not in the analysis and writing the report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16984"}}